CL2017002649A1 - Gránulos de monensina dispersables en agua por granulación húmeda. - Google Patents
Gránulos de monensina dispersables en agua por granulación húmeda.Info
- Publication number
- CL2017002649A1 CL2017002649A1 CL2017002649A CL2017002649A CL2017002649A1 CL 2017002649 A1 CL2017002649 A1 CL 2017002649A1 CL 2017002649 A CL2017002649 A CL 2017002649A CL 2017002649 A CL2017002649 A CL 2017002649A CL 2017002649 A1 CL2017002649 A1 CL 2017002649A1
- Authority
- CL
- Chile
- Prior art keywords
- monensin
- water
- wet granulation
- granules dispersible
- water dispersible
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
Abstract
<p>La presente invención se refiere a una formulación de gránulo dispersable en agua que comprenden desde aproximadamente 5% hasta aproximadamente 80% (p/p) de monensina; desde aproximadamente 1% hasta aproximadamente 20% (p/p) de uno o más tensoactivos; desde aproximadamente 1% hasta aproximadamente 30% (p/p) de uno o más aglutinantes; desde aproximadamente 1% hasta aproximadamente 90% (p/p) de uno o más rellenadores; y agua hasta aproximadamente 2% (p/p). La presente descripción también proporciona un proceso para la preparación de formulación de gránulo de monensina dispersable en agua. La presente descripción proporciona, además, un método para administrar una cantidad terapéuticamente efectiva de una formulación de gránulo de monensina dispersable en agua a un animal.</p>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562153592P | 2015-04-28 | 2015-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2017002649A1 true CL2017002649A1 (es) | 2018-04-20 |
Family
ID=55949105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2017002649A CL2017002649A1 (es) | 2015-04-28 | 2017-10-18 | Gránulos de monensina dispersables en agua por granulación húmeda. |
Country Status (14)
Country | Link |
---|---|
US (1) | US10117849B2 (es) |
EP (1) | EP3288535A1 (es) |
JP (1) | JP6403242B2 (es) |
KR (1) | KR102060234B1 (es) |
CN (1) | CN107530286B (es) |
AU (1) | AU2016254983B2 (es) |
CA (1) | CA2978016C (es) |
CL (1) | CL2017002649A1 (es) |
EA (1) | EA033344B1 (es) |
HK (1) | HK1245656A1 (es) |
MX (1) | MX2017013693A (es) |
NZ (1) | NZ735038A (es) |
WO (1) | WO2016176121A1 (es) |
ZA (1) | ZA201706186B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR102019008505A2 (pt) * | 2019-04-26 | 2020-11-03 | Mônica Filomena Assis De Souza | Composição homeopática para tratamento de animais domésticos, silvestres, peixes, anfíbios e outros |
KR20210015545A (ko) | 2019-08-02 | 2021-02-10 | 주식회사 파인드커넥트 | 수익공유형 온라인 광고 서비스 시스템 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3475375A (en) * | 1967-06-23 | 1969-10-28 | Du Pont | Novel amorphous guanidine silicates,and compositions thereof with synthetic resins |
IL70015A0 (en) | 1983-10-20 | 1984-01-31 | Koffolk 1949 Ltd | Ionophore antibiotic compositions and processes for the preparation thereof |
US5443764A (en) * | 1987-07-01 | 1995-08-22 | Ici Australia Operations Propietary Limited | Water-dispersible granules |
CA2225741C (en) * | 1995-07-14 | 2006-10-03 | Eli Lilly & Co (Nz) Limited | Ionophore antibiotic formulations |
NZ272574A (en) | 1995-07-14 | 1999-02-25 | Lilly Eli & Co Nz Ltd | Aqueous base suspension concentrate containing at least one ionophore antibiotic and wetting agent and/or a surfactant and xanthan gum optionally with a suspension agent, an antifreeze agent and an antifoaming agent; drench for veterinary treatment |
NZ280384A (en) * | 1995-11-02 | 1997-01-29 | Lilly Eli & Co Nz Ltd | Animal feed supplement comprising a wettable powder composition of an ionophore antibiotic |
WO1997016195A1 (en) * | 1995-11-02 | 1997-05-09 | Eli Lilly & Company (Nz) Limited | Wettable powder compositions of ionophore antibiotics |
US6612044B2 (en) * | 2000-02-01 | 2003-09-02 | Faro Technologies, Inc. | Method, system and storage medium for providing an executable program to a coordinate measurement system |
AU1650302A (en) * | 2000-12-19 | 2002-07-01 | Eli Lilly And Company Nz Ltd | Ionophore antibiotic formulations |
CN102525880B (zh) * | 2010-12-31 | 2014-06-11 | 正大天晴药业集团股份有限公司 | 一种阿瑞匹坦固体分散组合物 |
NZ596017A (en) | 2011-10-26 | 2014-04-30 | Glenmark Ip Ltd | Ionophore antibiotic veterinary composition and method of manufacture |
KR101473851B1 (ko) * | 2013-01-25 | 2014-12-18 | 대한뉴팜(주) | 모넨신을 주성분으로 하는 가축의 콕시듐증 예방용 펠릿형 조성물 및 그의 제조방법 |
US9648872B2 (en) * | 2014-02-19 | 2017-05-16 | Deepak Pranjivandas Shah | Water dispersible granule composition |
-
2016
- 2016-04-22 AU AU2016254983A patent/AU2016254983B2/en active Active
- 2016-04-22 JP JP2017556219A patent/JP6403242B2/ja active Active
- 2016-04-22 MX MX2017013693A patent/MX2017013693A/es active IP Right Grant
- 2016-04-22 EA EA201792104A patent/EA033344B1/ru not_active IP Right Cessation
- 2016-04-22 CA CA2978016A patent/CA2978016C/en active Active
- 2016-04-22 CN CN201680024313.8A patent/CN107530286B/zh active Active
- 2016-04-22 EP EP16721314.9A patent/EP3288535A1/en active Pending
- 2016-04-22 US US15/556,654 patent/US10117849B2/en active Active
- 2016-04-22 KR KR1020177030711A patent/KR102060234B1/ko active IP Right Grant
- 2016-04-22 WO PCT/US2016/028932 patent/WO2016176121A1/en active Application Filing
- 2016-04-22 NZ NZ735038A patent/NZ735038A/en unknown
-
2017
- 2017-09-12 ZA ZA2017/06186A patent/ZA201706186B/en unknown
- 2017-10-18 CL CL2017002649A patent/CL2017002649A1/es unknown
-
2018
- 2018-04-23 HK HK18105252.2A patent/HK1245656A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP2018515465A (ja) | 2018-06-14 |
CN107530286A (zh) | 2018-01-02 |
US10117849B2 (en) | 2018-11-06 |
US20180042888A1 (en) | 2018-02-15 |
CA2978016A1 (en) | 2016-11-03 |
JP6403242B2 (ja) | 2018-10-10 |
CN107530286B (zh) | 2021-11-16 |
EA033344B1 (ru) | 2019-09-30 |
MX2017013693A (es) | 2018-03-02 |
AU2016254983B2 (en) | 2018-07-19 |
ZA201706186B (en) | 2020-01-29 |
CA2978016C (en) | 2019-11-26 |
HK1245656A1 (zh) | 2018-08-31 |
EA201792104A1 (ru) | 2018-03-30 |
BR112017018496A2 (pt) | 2018-04-17 |
KR102060234B1 (ko) | 2019-12-27 |
KR20170130563A (ko) | 2017-11-28 |
EP3288535A1 (en) | 2018-03-07 |
AU2016254983A1 (en) | 2017-09-14 |
NZ735038A (en) | 2018-05-25 |
WO2016176121A1 (en) | 2016-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501226A1 (en) | Methods for treating huntingtons disease | |
CL2017000379A1 (es) | Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7) | |
CL2017002727A1 (es) | Composiciones de ácido obeticólico y métodos de uso | |
CR11137A (es) | Valvulas prosteticas de corazon | |
CL2016001874A1 (es) | Forma de dosificación oral sólida de liberación modificada que comprende pridopidina y un excipiente de control de velocidad; formulación farmacéutica que comprende a la forma de dosificación; uso de la forma de dosificación o de la formulación farmacéutica para tratar una enfermedad neurodegenerativa o relacionada con dopamina, como la enfermedad de huntington, entre otras. | |
ECSP109984A (es) | Composición farmacéutica mejorada que contiene dihidropiridina, antagonista del canal de calcio y el método para su preparación | |
MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
CL2015003072A1 (es) | Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas. | |
MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
CO2018003224A2 (es) | Formulaciones de aminoacidos de liberacion modificada administradas oralmente | |
BR112017004393A2 (pt) | formulações de anticorpo | |
BR112018003526A2 (pt) | métodos de tratamento de doenças inflamatórias | |
CL2016003283A1 (es) | Formulación compuesta para administración oral que comprende ezetimiba y rosuvastatina y un procedimiento para su preparación | |
EP3031464A4 (en) | Preventive or therapeutic agent for ruminant animal mastitis | |
AR128459A2 (es) | Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación | |
EA201692043A1 (ru) | Лекарственная форма иммунодепрессанта | |
WO2016038521A8 (en) | Pharmaceutical compositions of liraglutide | |
SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
CL2017002649A1 (es) | Gránulos de monensina dispersables en agua por granulación húmeda. | |
PH12015502717A1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
MX2016011572A (es) | Composiciones antimicrobianas de acido organico. | |
GB2536599A (en) | Larvicidal composition | |
WO2016197042A8 (en) | Modified or targeted release formulations of linaclotide | |
MX2017011300A (es) | Composicion insecticida a base de agua para vaporizarse y difundirse al calentarse, y metodo para vaporizar y difundir dicha composicion por medio de calentamiento. | |
IN2013MU03428A (es) |